[{"quiz_id": "ABMS20260101_kimi-k2-thinking_p03", "question_id": "ABMS20260101_kimi-k2-thinking_p03-001", "question": "A 64-year-old man with metastatic hemangiopericytoma presents with refractory hypoglycemia (glucose 28 mg/dL) despite 20% dextrose infusion at 100 mL/hour. Labs show insulin <2 μIU/mL, C-peptide 0.1 ng/mL, IGF-2 850 ng/mL (normal 50-200), and IGF-2:IGF-1 ratio 12:1. Which immediate pharmacologic intervention is most likely to achieve euglycemia within 24 hours?", "options": ["Continuous hydrocortisone infusion 10 mg/hour", "Recombinant IGF-1 40 mg subcutaneously twice daily", "Diazoxide 300 mg orally three times daily", "Octreotide 200 μg subcutaneously three times daily", "Glucagon 2 mg intramuscularly every 4 hours"], "answer": "A", "answer_index": 0, "explanation": "High-dose glucocorticoids suppress aberrant IGF-2 production from the tumor, correcting hypoglycemia within hours. Recombinant IGF-1 (B) worsens the IGF-2:IGF-1 imbalance. Diazoxide (C) and octreotide (D) are ineffective in non-islet cell tumor hypoglycemia due to suppressed insulin. Glucagon (E) provides only transient effect and cannot sustain normoglycemia.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Endocrine", "abms_specialty": "Endocrine", "abms_source": "topics_mapped", "source_label_raw": "endocrinology", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-003", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed123.jsonl", "pred": "A", "model_outputs": "The clinical presentation and laboratory findings are classic for non-islet cell tumor hypoglycemia (NICTH), a paraneoplastic syndrome most commonly associated with large mesenchymal tumors like hemangiopericytomas (solitary fibrous tumors). The pathophysiology involves the tumor secretion of a high-molecular-weight form of IGF-2 (\"big\" IGF-2). This molecule binds to insulin receptors and increases glucose utilization while suppressing hepatic glucose output. It also suppresses endogenous growth hormone (GH) secretion, leading to low levels of IGF-1 and IGF-binding protein 3 (IGFBP-3). The diagnostic hallmarks are hypoglycemia with suppressed insulin and C-peptide levels, normal or elevated total IGF-2, and a high IGF-2:IGF-1 ratio (usually >10).\n\nPharmacologic management of NICTH:\n1.  Glucocorticoids (Option A): High-dose glucocorticoids are the most effective medical therapy for NICTH. They work through multiple mechanisms: they stimulate gluconeogenesis, induce insulin resistance (counteracting the hypoglycemic effect of big IGF-2), and, crucially, can decrease the circulating levels of big IGF-2, possibly by increasing its clearance or suppressing tumor production. A continuous infusion of hydrocortisone (or oral high-dose prednisone/dexamethasone) typically restores euglycemia within a relatively short period (often <24 hours).\n2.  Recombinant IGF-1 (Option B): Recombinant IGF-1 (mecasermin) is an insulin agonist and causes hypoglycemia as a major side effect. It would worsen the patient's condition. The treatment that involves the IGF axis is recombinant *human growth hormone* (rhGH), which stimulates production of IGF-1 and IGFBP-3. The increased IGFBP-3 binds the big IGF-2, preventing it from activating insulin receptors. However, rhGH takes days to be fully effective.\n3.  Diazoxide (Option C): Diazoxide inhibits insulin secretion from pancreatic beta cells. Since this patient's insulin levels are already appropriately suppressed (<2 μIU/mL) due to the feedback from the hypoglycemia caused by IGF-2, diazoxide would be ineffective.\n4.  Octreotide (Option D): Somatostatin analogs are occasionally used but are generally less consistent in efficacy for NICTH compared to glucocorticoids. They may help if the tumor expresses somatostatin receptors, but glucocorticoids are the standard first-line pharmacologic addition to dextrose.\n5.  Glucagon (Option E): While glucagon stimulates hepatic glucose output, its efficacy is transient and limited by hepatic glycogen stores, which may already be depleted in a patient with refractory hypoglycemia. It does not address the underlying pathophysiology as effectively as glucocorticoids in this syndrome.\n\nThe answer is (A)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p03", "question_id": "ABMS20260101_kimi-k2-thinking_p03-002", "question": "A 42-year-old man with MEN1 syndrome (germline MEN1 c.628_631del) is found to have a 2.8 cm duodenal gastrinoma with 3 regional periduodenal lymph node metastases on Ga-68 DOTATATE PET/CT. Serum gastrin is 2,200 pg/mL with gastric pH <2. He has no pancreatic lesions. What is the optimal surgical management?", "options": ["A) Whipple pancreaticoduodenectomy with pylorus preservation", "B) Pancreas-preserving duodenectomy with regional lymphadenectomy", "C) Endoscopic submucosal dissection of the duodenal tumor", "D) Long-acting octreotide 30 mg monthly without surgery", "E) Tumor enucleation through duodenotomy only"], "answer": "B", "answer_index": 1, "explanation": "For large duodenal neuroendocrine tumors in MEN1, pancreas-preserving duodenectomy achieves oncologic clearance while preserving pancreatic function, which is critical as these patients inevitably develop pancreatic neuroendocrine tumors requiring future pancreatic surgery. Whipple procedure is excessively morbid for duodenal disease alone.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "abms_specialty": "Gastrointestinal", "abms_source": "target_topic", "source_label_raw": "Gastrointestinal", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-003", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed131.jsonl", "pred": "A", "model_outputs": "This patient has Multiple Endocrine Neoplasia type 1 (MEN1) and presents with Zollinger-Ellison Syndrome (ZES). The key features of the case are the size of the duodenal gastrinoma (2.8 cm) and the presence of regional lymph node metastases.\n\n1.  Indications for Surgery: In patients with MEN1-associated ZES, surgical management is controversial for small tumors. However, current consensus guidelines (e.g., NCCN, ENETS, NANETS) recommend surgical resection for tumors >2 cm to reduce the risk of distant (liver) metastasis and improve disease-specific survival. This patient has a 2.8 cm tumor and proven nodal metastases, clearly indicating surgery over medical management alone (Option D).\n\n2.  Surgical Approach: The goal of surgery is to remove the primary tumor and involved lymph nodes.\n    *   Option C (Endoscopic submucosal dissection): This is contraindicated because the tumor is large, likely transmural/submucosal, and most importantly, ESD cannot address the documented lymph node metastases.\n    *   Option E (Tumor enucleation through duodenotomy only): The phrasing \"only\" implies that a lymphadenectomy is not performed. Since the patient has proven lymph node metastases, enucleation of the primary tumor *without* lymph node dissection is oncologically inadequate. Standard \"conservative\" surgery for MEN1 involves enucleation *plus* anatomical regional lymphadenectomy (Thompson procedure). Since the option explicitly limits the procedure to enucleation only, it is incorrect.\n    *   Option B (Pancreas-preserving duodenectomy): While pancreatic-sparing total duodenectomy has been described as a theoretical \"middle ground\" to remove the gastrinoma-prone duodenal tissue while sparing the pancreas, it is a technically complex, non-standard procedure with significant risks of ischemia and biliary/pancreatic complications. It is not the standard of care.\n    *   Option A (Whipple pancreaticoduodenectomy with pylorus preservation): For large (>2 cm) duodenal gastrinomas, especially those with lymph node involvement, a pancreaticoduodenectomy (Whipple) is often required to achieve R0 resection and adequate lymph node clearance. In the context of MEN1, where gastrinomas are typically multiple and located in the proximal duodenum (the \"gastrinoma triangle\"), the Whipple procedure provides the highest chance of biochemical cure by removing the target organ and regional nodes. While more morbid than local excision, it becomes the optimal choice when the tumor is large, nodes are positive, and the alternative (local excision) is not presented with the necessary nodal dissection in the options.\n\nGiven the tumor size (2.8 cm) and nodal positivity, and the inadequacy of \"enucleation only\" (leaving positive nodes), the Whipple procedure is the single best surgically valid option listed.\n\nThe answer is (A)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p03", "question_id": "ABMS20260101_kimi-k2-thinking_p03-003", "question": "A 59-year-old woman with rheumatoid arthritis on methotrexate develops progressive dyspnea and weight loss. HRCT demonstrates upper lobe-predominant pleural thickening, subpleural consolidation, and traction bronchiectasis with severe volume loss. Surgical lung biopsy shows dense subpleural fibrosis with prominent elastic fiber deposition and minimal inflammation, extending into the pleura. Which histopathologic finding most strongly differentiates this from usual interstitial pneumonia?", "options": ["Fibroblast foci within alveolar walls", "Honeycomb change with mucin-filled cysts", "Presence of intra-alveolar fibroblastic plugs", "Elastosis involving visceral pleura and subpleural parenchyma", "Patchy temporally heterogeneous fibrosis"], "answer": "D", "answer_index": 3, "explanation": "Pleuroparenchymal fibroelastosis (PPFE) is defined by characteristic elastosis of both pleura and subpleural parenchyma, which is absent in UIP. Fibroblast foci (A) and honeycomb change (B) are hallmark UIP features. Intra-alveolar fibroblastic plugs (C) suggest organizing pneumonia. Patchy heterogeneous fibrosis (E) is typical of UIP, whereas PPFE shows uniform elastotic fibrosis.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pulmonary", "abms_specialty": "Pulmonary", "abms_source": "topics_mapped", "source_label_raw": "pulmonology", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-004", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed123.jsonl", "pred": "D", "model_outputs": "The patient's clinical presentation (RA, upper-lobe predominant fibrosis, pleural thickening) and histologic findings (dense subpleural fibrosis with prominent elastic fiber deposition) are characteristic of Pleuroparenchymal Fibroelastosis (PPFE). PPFE is a distinct interstitial pneumonia that can be idiopathic or associated with conditions like autoimmune disease (e.g., rheumatoid arthritis) and lung transplantation.\n\nThe key histologic feature that defines PPFE and differentiates it from Usual Interstitial Pneumonia (UIP) and other interstitial lung diseases is the nature of the fibrosis. In PPFE, there is marked elastosis (abundance of elastic fibers) within the fibrosis involving the visceral pleura and the subpleural parenchyma. In contrast, the fibrosis in UIP is predominantly collagenous, temporally heterogeneous (patchy, with fibroblast foci), and typically lower-lobe predominant. While UIP shows fibroblast foci and honeycomb change, these are not the defining features of the case described. The prominent elastic fiber deposition described in the biopsy is the specific discriminator.\n\nThe answer is (D)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p03", "question_id": "ABMS20260101_kimi-k2-thinking_p03-004", "question": "A 35-year-old woman with CFH p.Arg1215Gln mutation undergoes deceased donor kidney transplantation. On postoperative day 7, she develops rising creatinine (3.4 mg/dL), thrombocytopenia (45,000/μL), schistocytes, and hemolysis. Eculizumab 900 mg weekly was started preemptively on day 0. Platelets normalize by day 10 but creatinine continues to rise to 4.8 mg/dL. What is the next step?", "options": ["A) Increase eculizumab dose to 1,200 mg weekly", "B) Initiate daily plasma exchange with fresh frozen plasma", "C) Switch to ravulizumab 3,600 mg maintenance dose", "D) Measure eculizumab trough level and CH50 activity", "E) Proceed with transplant nephrectomy"], "answer": "D", "answer_index": 3, "explanation": "Breakthrough atypical HUS despite eculizumab requires therapeutic drug monitoring to distinguish underdosing from complement amplification via properdin or C5 gain-of-function mutation. Pharmacokinetic assessment guides therapy rather than empiric dose escalation or ineffective plasma exchange.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "abms_specialty": "Nephrology", "abms_source": "target_topic", "source_label_raw": "Nephrology", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-005", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed131.jsonl", "pred": "D", "model_outputs": "This patient with a known CFH mutation (associated with atypical Hemolytic Uremic Syndrome, aHUS) underwent kidney transplantation and was treated preemptively with eculizumab. Despite this, she developed signs of thrombotic microangiopathy (TMA) on postoperative day 7 (breakthrough TMA). Although her platelet count has normalized by day 10, her creatinine continues to rise.\n\nIn the setting of treated aHUS, normalization of platelet count is typically the earliest marker of hematologic response. However, persistent or worsening renal dysfunction can indicate either:\n1.  Incomplete complement blockade: The standard dose may not be sufficient to suppress the massive complement activation triggered by the transplant surgery and ischemia-reperfusion injury.\n2.  Other causes of renal injury: Such as acute tubular necrosis (ATN) resulting from the initial TMA hit or surgery, antibody-mediated rejection, or drug toxicity.\n\nBecause the patient has shown a partial response (platelets normalized) but not a full response (kidney function worsening), it is crucial to determine if the complement cascade is adequately inhibited before blindly increasing the dose or switching therapies.\n\nEculizumab efficacy is monitored by measuring CH50 (total hemolytic complement activity) and/or eculizumab trough levels.\n*   A CH50 < 10% (or undetectable) indicates complete C5 blockade. If the patient has complete blockade, the rising creatinine is likely due to ATN or another process (like rejection), and increasing the eculizumab dose would be of no benefit.\n*   If CH50 is detectable (> 10%) or trough levels are low (< 50-100 µg/mL), the complement blockade is inadequate, and the dose or frequency of eculizumab should be increased (Option A would be the subsequent step *after* confirmation).\n\nTherefore, the most appropriate next management step is to assess the pharmacodynamic and pharmacokinetic efficacy of the treatment.\n\nThe answer is (D)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p03", "question_id": "ABMS20260101_kimi-k2-thinking_p03-005", "question": "A 28-year-old man is day +45 after matched unrelated donor allogeneic stem cell transplant for AML in CR1. He develops new hypertension (BP 165/100 mmHg), proteinuria (3.2 g/day), rising LDH (850 U/L), hemolysis, and thrombocytopenia. ADAMTS13 activity is 45%. Tacrolimus was stopped 14 days ago for rising creatinine. What is the appropriate therapy?", "options": ["A) Eculizumab 900 mg weekly IV", "B) High-dose methylprednisolone 1 g IV x3 days plus plasma exchange", "C) Rituximab 375 mg/m2 weekly for 4 doses", "D) Resume tacrolimus and target level 8-10 ng/mL", "E) Supportive care with aggressive blood pressure control only"], "answer": "A", "answer_index": 0, "explanation": "Transplant-associated thrombotic microangiopathy is mediated by complement activation independent of ADAMTS13; eculizumab blocks terminal complement and is the only effective therapy. Plasma exchange is ineffective; resuming calcineurin inhibitors worsens TMA.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "abms_specialty": "Hematology", "abms_source": "target_topic", "source_label_raw": "Hematology", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-006", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed131.jsonl", "pred": "A", "model_outputs": "This patient presents with signs and symptoms consistent with Transplant-Associated Thrombotic Microangiopathy (TA-TMA). Key features include:\n\n1.  Clinical Findings: New onset hypertension, significant proteinuria (3.2 g/day), rising LDH (suggesting tissue damage and hemolysis), and thrombocytopenia following allogeneic hematopoietic stem cell transplantation (HSCT).\n2.  Exclusion of TTP: The ADAMTS13 activity is 45%, which rules out Thrombotic Thrombocytopenic Purpura (TTP), where activity is typically <10%.\n3.  Refractory to CNI Withdrawal: The patient stopped Tacrolimus (a calcineurin inhibitor associated with TMA) 14 days ago, yet the TMA features (hemolysis, renal dysfunction) persist or have developed. This indicates that simple withdrawal of the inciting drug is insufficient.\n4.  High-Risk Classification: The presence of nephrotic-range proteinuria (>3 g/day) and hypertension classifies this as high-risk TA-TMA.\n\nAnalysis of Options:\n*   A) Eculizumab 900 mg weekly IV: Recent literature and consensus guidelines support the use of Eculizumab, a terminal complement inhibitor (anti-C5 antibody), for patients with high-risk TA-TMA. The pathophysiology involves endothelial injury and complement activation. High-risk features (like proteinuria) are associated with very high mortality if treated only with supportive care. Eculizumab has demonstrated significant improvement in survival and renal outcomes in this population.\n*   B) Plasma exchange (PEX): PEX is the treatment of choice for TTP. However, in TA-TMA, PEX has historically shown poor efficacy (response rates <50%) and high procedure-related mortality. Because ADAMTS13 is not severely deficient and autoantibodies are not the primary cause, PEX is not recommended.\n*   C) Rituximab: This is used for antibody-mediated processes (like TTP or autoimmune hemolytic anemia) or PTLD. It does not address the complement-mediated endothelial damage of TA-TMA.\n*   D) Resume tacrolimus: Calcineurin inhibitors are endothelial toxins and triggers for TA-TMA. Resuming tacrolimus would exacerbate the condition.\n*   E) Supportive care only: While blood pressure control is important, high-risk TA-TMA has a mortality rate exceeding 80% with supportive care alone. Targeted therapy is required.\n\nTherefore, Eculizumab is the most appropriate next step in therapy for high-risk TA-TMA.\n\nThe answer is (A)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p03", "question_id": "ABMS20260101_kimi-k2-thinking_p03-006", "question": "A 14-year-old girl with chronic atypical neutrophilic dermatosis, lipodystrophy, and recurrent fevers (CANDLE syndrome) has persistent inflammatory lesions and fevers despite anakinra 100 mg daily and canakinumab 150 mg monthly. Genetic testing confirms PSMB8 c.224C>T mutation. What is the next therapy?", "options": ["A) High-dose prednisone 1 mg/kg/day", "B) Baricitinib 4 mg daily (JAK1/2 inhibitor)", "C) Tocilizumab 8 mg/kg IV monthly", "D) Thalidomide 100 mg nightly", "E) Allogeneic stem cell transplant"], "answer": "B", "answer_index": 1, "explanation": "CANDLE syndrome is a type I interferonopathy due to proteasome dysfunction; JAK inhibitors block downstream interferon signaling and are effective when IL-1 blockade fails. Baricitinib has shown efficacy in refractory cases. Anti-IL-6 and thalidomide are ineffective; transplant is experimental.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "abms_specialty": "Immunology", "abms_source": "target_topic", "source_label_raw": "Immunology", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-007", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed131.jsonl", "pred": "B", "model_outputs": "Here is the reasoning for the selected answer:\n\n1.  Diagnosis and Pathophysiology: The patient has CANDLE syndrome (Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated temperature), which is confirmed by the *PSMB8* mutation. CANDLE syndrome is a type of proteasome-associated autoinflammatory syndrome (PRAAS). The underlying defect leads to proteasome dysfunction, accumulation of ubiquitinated proteins, and constitutive activation of the type I interferon (IFN) pathway (an interferonopathy).\n\n2.  Current Treatment Status: The patient has failed IL-1 inhibiting therapies (anakinra and canakinumab). While IL-1 blockade is effective for inflammasomopathies (like Cryopyrin-Associated Periodic Syndromes), it is generally ineffective or only partially effective in interferonopathies like CANDLE syndrome because the primary driver is interferon signaling, not IL-1beta.\n\n3.  Mechanism-Based Treatment: Since the disease is driven by type I interferon signaling, therapies that block this pathway are indicated. Type I interferons signal through the JAK-STAT pathway (specifically utilizing JAK1 and Tyk2/JAK2).\n\n4.  Evaluation of Options:\n    *   Baricitinib (Option B) is a selective JAK1/JAK2 inhibitor. It blocks the signaling downstream of the interferon receptor. Clinical studies, specifically work done at the NIH published in sources like the *New England Journal of Medicine*, have demonstrated that baricitinib is highly effective in controlling disease activity, normalizing inflammatory markers, and allowing for steroid tapering in patients with CANDLE syndrome and other interferonopathies. It is the drug of choice for this specific indication.\n    *   High-dose prednisone (Option A) might temporarily suppress inflammation but is associated with severe long-term toxicity and does not target the specific molecular pathway as effectively as JAK inhibitors.\n    *   Tocilizumab (Option C) targets IL-6. While IL-6 levels may be elevated, blocking it does not address the upstream interferon signature as effectively as JAK inhibition.\n    *   Thalidomide (Option D) is not a standard treatment for this condition.\n    *   Stem cell transplant (Option E) is a high-risk procedure reserved for life-threatening cases refractory to medical therapy. Since a targeted medical therapy (JAK inhibition) exists and has not yet been tried, transplant is not the next step.\n\nThe answer is (B)\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p03", "question_id": "ABMS20260101_kimi-k2-thinking_p03-007", "question": "An 8-year-old boy presents with recurrent fevers, livedo racemosa, recurrent lacunar strokes, and vasculitic neuropathy. Laboratory studies show low IgM, elevated IgA, and negative ANCA. Genetic testing confirms biallelic loss-of-function mutations in ADA2. Which biologic therapy is most effective for this condition?", "options": ["A) High-dose systemic glucocorticoids", "B) Intravenous cyclophosphamide", "C) Etanercept", "D) Anakinra", "E) Rituximab"], "answer": "C", "answer_index": 2, "explanation": "DADA2 (Deficiency of Adenosine Deaminase 2) causes vasculitis due to loss of ADA2 enzyme function, leading to macrophage polarization defects and TNF-alpha overproduction. Etanercept, a TNF-alpha inhibitor, is highly effective and can induce remission. Cyclophosphamide and steroids are less effective. Anakinra has variable response, and rituximab is ineffective as the disease is not B-cell mediated.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Rheumatology/Musculoskeletal", "abms_specialty": "Rheumatology/Musculoskeletal", "abms_source": "topics_mapped", "source_label_raw": "rheumatology", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-010", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed124", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed124.jsonl", "pred": "C", "model_outputs": "Based on the clinical presentation (recurrent fevers, livedo racemosa, early-onset strokes, vasculitic neuropathy) and the specific genetic finding of biallelic loss-of-function mutations in *ADA2*, the diagnosis is Deficiency of Adenosine Deaminase 2 (DADA2).\n\nDADA2 is an autoinflammatory disease and form of systemic vasculitis that clinically resembles polyarteritis nodosa (PAN). The associated inflammation is driven primarily by tumor necrosis factor (TNF). Clinical studies have demonstrated that anti-TNF agents are the most effective treatment for controlling inflammation and, crucially, for preventing recurrent strokes in these patients. Traditional immunosuppressants like steroids and cyclophosphamide are often insufficient to prevent ischemic events in DADA2.\n\nTherefore, the TNF inhibitor Etanercept (or adalimumab) is the treatment of choice among the options listed.\n\nThe answer is (C)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p03", "question_id": "ABMS20260101_kimi-k2-thinking_p03-008", "question": "A 38-year-old man from Vietnam with chronic mucocutaneous candidiasis is found to have STAT1 gain-of-function c.821T>C mutation. He presents with disseminated umbilicated papular skin lesions, hepatosplenomegaly, and fevers. Skin biopsy shows intracellular yeast forms with central septation. What is optimal therapy?", "options": ["A) Liposomal amphotericin B 5 mg/kg/day alone for 14 days", "B) Voriconazole 6 mg/kg IV q12h then 4 mg/kg maintenance", "C) Liposomal amphotericin B induction then itraconazole maintenance plus ruxolitinib 10 mg BID", "D) Caspofungin 70 mg loading then 50 mg daily", "E) Fluconazole 800 mg loading then 400 mg daily"], "answer": "C", "answer_index": 2, "explanation": "STAT1 GOF causes defective Th17 immunity leading to refractory dimorphic fungal infections. Talaromyces marneffei requires initial amphotericin induction followed by itraconazole maintenance. Adding JAK inhibition (ruxolitinib) reverses the underlying immunodeficiency and is essential for cure.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "abms_specialty": "Infectious Disease", "abms_source": "target_topic", "source_label_raw": "Infectious Disease", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-008", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed131.jsonl", "pred": "C", "model_outputs": "The patient is a 38-year-old man from Vietnam presenting with signs of disseminated fungal infection. The specific findings of umbilicated papular skin lesions, hepatosplenomegaly, and \"intracellular yeast forms with central septation\" are pathognomonic for Talaromycosis (caused by *Talaromyces marneffei*, formerly *Penicillium marneffei*). This fungus is endemic to Southeast Asia and reproduces by binary fission, creating the characteristic central septation, unlike the budding seen in *Histoplasma*.\n\nThe patient also has a known _STAT1_ gain-of-function (GOF) mutation. This genetic defect leads to hyperactive STAT1 signaling, which suppresses Th17 immunity (causing Chronic Mucocutaneous Candidiasis) and impairs responses to intracellular pathogens (increasing susceptibility to viral, mycobacterial, and fungal infections like *Talaromyces*).\n\nTreatment Analysis:\n1.  Antifungal Principles for Talaromycosis: Current guidelines for severe or disseminated Talaromycosis recommend induction therapy with Liposomal Amphotericin B (or deoxycholate) followed by consolidation and maintenance therapy with Itraconazole.\n    *   Caspofungin (Option D) has no meaningful activity against *T. marneffei*.\n    *   Fluconazole (Option E) is significantly less effective than itraconazole and is not recommended.\n    *   Voriconazole (Option B) is effective but usually reserved as an alternative; Amphotericin B is the gold standard for induction in severe cases.\n    *   Option A (Amphotericin B alone for 14 days) is incorrect because it lacks the necessary maintenance therapy; relapse is inevitable without it.\n\n2.  Management of _STAT1_ GOF: The underlying immunodeficiency is driven by the JAK-STAT pathway. Ruxolitinib, a JAK1/2 inhibitor, dampens the hyperactive signaling, partially restoring immune function and aiding in the clearance of difficult infections like CMC and disseminated fungi in these patients.\n\nOption C correctly combines the standard-of-care antifungal regimen for severe Talaromycosis (Amphotericin B induction followed by Itraconazole maintenance) with the targeted immunotherapy (Ruxolitinib) indicated for the patient's specific genetic mutation.\n\nThe answer is (C)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p03", "question_id": "ABMS20260101_kimi-k2-thinking_p03-009", "question": "A 72-year-old woman with metastatic melanoma on combination ipilimumab/nivolumab develops six watery stools daily. Laboratory studies show AST 180 U/L (upper limit of normal 40), ALT 220 U/L, and normal bilirubin. Colonoscopy reveals ulcerative colitis-like changes. What is the next step in management?", "options": ["Start prednisone 1 mg/kg plus infliximab 5 mg/kg", "Start prednisone 1 mg/kg plus vedolizumab 300 mg", "Start prednisone 1 mg/kg; if no improvement in 3-5 days add vedolizumab", "Hold immunotherapy and observe", "Start mycophenolate mofetil 1 g twice daily"], "answer": "C", "answer_index": 2, "explanation": "Grade 3 immune-related colitis with concurrent grade 2 hepatitis requires high-dose steroids (1-2 mg/kg prednisone). Infliximab is contraindicated in grade ≥2 hepatitis due to hepatotoxicity risk. Vedolizumab is the preferred second-line agent for steroid-refractory colitis without hepatic toxicity, but should be added only after 3-5 days of steroid failure rather than empirically.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "abms_specialty": "Medical Oncology", "abms_source": "target_topic", "source_label_raw": "Medical Oncology", "source_quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "source_question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-003", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251225T234023630Z_kimi-k2-thinking_seed133", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251225T234023630Z_kimi-k2-thinking_seed133.jsonl", "pred": "C", "model_outputs": "The clinical scenario describes a patient with metastatic melanoma treated with combination immunotherapy (ipilimumab/nivolumab) who presents with immune-mediated colitis (IMC) and concurrent immune-mediated hepatitis.\n\n1.  Assessment of Severity:\n    *   Colitis: 6 watery stools daily is consistent with Grade 2/3 colitis. The presence of \"ulcerative colitis-like changes\" on colonoscopy confirms the immune-mediated etiology and significant inflammation.\n    *   Hepatitis: AST 180 U/L (4.5x ULN) and ALT 220 U/L indicate Grade 2 (3–5x ULN) or borderline Grade 3 hepatitis.\n\n2.  Standard Management Guidelines (ASCO, NCCN, SITC):\n    *   The first-line treatment for Grade 2/3 immune-mediated colitis is initiation of systemic corticosteroids, typically prednisone 1–2 mg/kg/day (or IV methylprednisolone).\n    *   If symptoms do not improve after 48–72 hours of high-dose steroids (steroid-refractory), a biologic agent is indicated.\n    *   Choice of Biologic:\n        *   Infliximab (TNF-alpha inhibitor) is the standard first-line biologic for steroid-refractory IMC. However, it carries a risk of hepatotoxicity and is generally contraindicated (or requires extreme caution) in patients with moderate-to-severe hepatic enzyme elevation.\n        *   Vedolizumab (alpha-4/beta-7 integrin antagonist) is gut-selective and has a favorable safety profile regarding the liver. It is the preferred biologic for IMC in patients with concurrent hepatitis or those contraindicated for TNF inhibitors.\n\n3.  Evaluating the Options:\n    *   A: Incorrect. Infliximab should be avoided due to the patient's elevated transaminases (hepatitis).\n    *   B: Incorrect. While vedolizumab is the correct biologic, standard of care dictates a trial of corticosteroids *before* adding biologics, rather than starting them concurrently upfront, unless the colitis is life-threatening (Grade 4) or prolonged.\n    *   C: Correct. This follows the standard stepwise algorithm: start corticosteroids (to treat both colitis and hepatitis), and if the colitis proves refractory (no improvement in a few days), add the liver-safe biologic vedolizumab.\n    *   D: Incorrect. Appropriate treatment is required; observation is unsafe for this grade of toxicity.\n    *   E: Incorrect. Mycophenolate is primarily used for steroid-refractory hepatitis, not as the primary rescue for colitis (where biologics are preferred), and steroids are the first step regardless.\n\nThe phrase \"if no improvement in 3-5 days\" in Option C aligns with the clinical practice of assessing steroid responsiveness before escalating therapy.\n\nThe answer is (C)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p03", "question_id": "ABMS20260101_kimi-k2-thinking_p03-010", "question": "A 42-year-old woman with lifelong idiopathic anaphylaxis, chronic urticaria, joint hypermobility, and baseline serum tryptase of 35 ng/mL is found to have heterozygous TPSAB1 copy number gain (α-tryptasemia). Symptoms persist despite high-dose cetirizine 40 mg daily and omalizumab 300 mg monthly. What is next therapy?", "options": ["A) Increase omalizumab to 600 mg monthly", "B) Prophylactic prednisone 10 mg daily", "C) Cromolyn sodium 200 mg QID", "D) Ketotifen 2 mg BID (mast cell stabilizer)", "E) Allergen immunotherapy based on skin testing"], "answer": "D", "answer_index": 3, "explanation": "Hereditary Alpha-Tryptasemia Syndrome causes constitutive mast cell activation; ketotifen stabilizes mast cell membranes and is effective when antihistamines fail. Omalizumab has variable efficacy; cromolyn is poorly absorbed systemically. Steroids are not prophylactic therapy.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "abms_specialty": "Allergy/Immunology", "abms_source": "target_topic", "source_label_raw": "Allergy/Immunology", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-010", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed131.jsonl", "pred": "A", "model_outputs": "The patient presents with symptoms consistent with Hereditary Alpha-Tryptasemia (H$\\alpha$T), characterized by elevated baseline tryptase (>11.4 ng/mL), cutaneous symptoms (urticaria, flushing), anaphylaxis, and connective tissue abnormalities (joint hypermobility). The genetic finding of *TPSAB1* copy number gain confirms the diagnosis.\n\nThe patient is currently treated with high-dose H1-antihistamines (cetirizine 40 mg) and standard-dose omalizumab (300 mg monthly). Despite this, she remains symptomatic with urticaria and anaphylaxis.\n\nGuideline-based management for Chronic Spontaneous Urticaria (CSU) and Idiopathic Anaphylaxis typically follows a stepwise approach:\n1.  Standard dose H1-antihistamines.\n2.  High-dose H1-antihistamines (up to 4-fold).\n3.  Add Omalizumab (usually 300 mg monthly).\n4.  If symptoms persist, options include increasing the dose of Omalizumab (off-label dosage up to 600 mg), shortening the dosing interval, or adding other immunosuppressants like cyclosporine.\n\nGiven the patient's refractory symptoms on 300 mg of omalizumab, the most appropriate next step in therapy, according to urticaria guidelines and expert consensus on managing refractory idiopathic anaphylaxis (especially in the context of high mast cell burden/tryptase), is to increase the dose of omalizumab. Doses of 450 mg or 600 mg are frequently utilized in patients who do not achieve complete control with the standard dose.\n\nOther options are less suitable:\n*   Prophylactic prednisone is generally avoided for long-term management due to toxicity.\n*   Cromolyn sodium has poor oral bioavailability and is less effective for systemic/cutaneous symptoms compared to GI symptoms.\n*   Ketotifen is a valid option for mast cell activation but is generally considered less potent than optimizing biologic therapy for severe anaphylaxis/urticaria; additionally, the patient is already on a high-dose antihistamine.\n*   Allergen immunotherapy is generally not indicated for *idiopathic* anaphylaxis (no allergen identified) and carries a high risk of adverse reactions in patients with uncontrolled mast cell activation and elevated baseline tryptase.\n\nThe answer is (A)"}]